What happened with PROF today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Profound Medical supplies hospitals and independent imaging centers with equipment that uses ultrasound energy to heat and destroy tissue selected by a physician. Its main commercial focus is TULSA-PRO, which treats prostate tissue through an ultrasound device inserted into the urethra. MRI images and temperature readings guide the treatment. Providers pay for the system, then buy single-use devices for each patient treated and related services. These recurring purchases provide most of the company’s revenue, and the United States is its largest market.
The company also sells Sonalleve, which delivers focused ultrasound from outside the body under MRI guidance. Marketed mainly outside North America, it has authorized uses that vary by country, including uterine fibroids and certain bone conditions. It earns money mainly through equipment sales, with limited recurring service revenue.
Revenue depends on clinicians adopting the procedures, facilities using the installed systems, and insurers and government programs providing adequate coverage and reimbursement. Use also requires compatible MRI scanners: TULSA-PRO works with selected Philips, Siemens and GE Healthcare scanners, while Sonalleve works with a Philips scanner. In the United States, TULSA-PRO’s FDA clearance covers ablation of prostate tissue, not treatment of a particular disease or condition.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Profound Medical Corp.’s growth hinges on adoption and use of prostate-ablation treatments, with Sonablate and Insightec adding ultrasound competition and MRI compatibility depending on platforms from Philips, Siemens and GE HealthCare.
EDAP TMS S.A.’s Focal One competes with Profound Medical Corp.’s TULSA-PRO for clinicians and hospitals choosing equipment that uses ultrasound to destroy prostate tissue. Watch Focal One equipment sales and recurring consumables and maintenance revenue for signs of adoption and use of this rival treatment.
PROCEPT BioRobotics Corporation competes with Profound Medical Corp.’s TULSA-PRO for hospitals’ prostate-treatment equipment spending and procedures, particularly for enlarged prostates: its AquaBeam and HYDROS systems use image-guided robotic waterjets to remove tissue, rather than ultrasound ablation. Watch sales of these systems and their single-use handpieces to gauge uptake of this alternative.
AngioDynamics, Inc.’s NanoKnife competes with Profound Medical Corp.’s ultrasound-based TULSA-PRO as an option for urologists and hospitals treating selected areas of prostate tissue; NanoKnife uses irreversible electroporation for ablation.
Profound Medical Corp. earningsThis company
Profound Medical's report will show whether sales of its treatment systems are also bringing in more revenue from single-use devices and services.
Read capital-equipment revenue alongside recurring non-capital revenue, which mainly comes from devices used for treatments and extended-warranty services. If both rise, system sales are growing alongside follow-on use and service income. If system sales rise but recurring revenue lags, equipment sales are not yet producing the same follow-through. That shows whether Profound Medical is turning system sales into ongoing use.
EDAP TMS S.A. earningsFOCL
EDAP TMS's report will show whether hospitals are buying and using Focal One, an ultrasound treatment system that competes with Profound Medical's TULSA-PRO for clinicians and hospitals.
Read Focal One equipment sales alongside recurring revenue from consumables and maintenance. If both rise, hospitals are not just buying this ultrasound system but continuing to use it, showing that clinicians and hospitals are adopting the competing approach. If equipment sales rise but recurring revenue lags, purchases have not yet translated into the same ongoing use. The first pattern shows an alternative gaining ground among the hospitals and clinicians Profound Medical also seeks; the second points to less evidence of sustained use.
